Mar 27, 2020- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month
Mar 18, 2020- The test will be used on the company's m2000 RealTime system that is currently available in hospitals and molecular laboratories in the U.S.- Abbott shipping 150,000 laboratory tests immediately; tests already sent to hospital and academic medical center labs in 18 states including Illinois, California, New York, Massachusetts and Washington- Company scaling up production at its U.S. manufacturing location to reach capacity for 1 million tests per week by end of March- Mar 5, 2020- New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases- The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery- Approval of the new delivery system follows first implants of the company's next-generation and investigational Navitor™ TAVI valve